DERP6 Antibody

What is DERP6 and what cellular functions does it perform?

DERP6 is a 316 amino acid protein that localizes to the cytoplasm and exists as multiple alternatively spliced isoforms. It has been characterized as ELP5, an essential subunit of the Elongator complex which promotes RNA polymerase II transcript elongation through histone acetylation in the nucleus and tRNA modification in the cytoplasm . DERP6/ELP5 plays a crucial structural role in the Elongator complex by connecting ELP3 to ELP4, thereby maintaining the integrity of the entire complex . Through its role in the Elongator complex, DERP6 is involved in numerous biological processes ranging from exocytosis in yeast to cell migration and neuronal differentiation in higher eukaryotes . Additionally, DERP6 is thought to participate in p53-mediated transcriptional regulation, suggesting its potential involvement in cellular stress responses and genomic stability maintenance .

What is the genomic context and expression pattern of DERP6?

The gene encoding DERP6 maps to human chromosome 17, which comprises over 2.5% of the human genome and encodes more than 1,200 genes . This chromosome is significant as it contains two key tumor suppressor genes, p53 and BRCA1, both directly involved in DNA repair processes . DERP6 is expressed ubiquitously throughout the body, with highest expression levels detected in liver, heart, testis, brain, and skeletal muscle tissues . This widespread expression pattern aligns with its fundamental role in transcriptional regulation through the Elongator complex, which affects multiple cellular processes across diverse tissue types.

How does DERP6 function within the Elongator complex?

DERP6 functions as the ELP5 subunit within the six-subunit Elongator complex (Elp1-Elp6). Biochemical analyses have revealed that DERP6/ELP5 serves as a critical structural component that directly connects ELP3 (the catalytic subunit with acetyltransferase activity) to ELP4 . This positioning is essential for maintaining the integrity of the entire complex. Experimental evidence from depletion studies shows that without DERP6/ELP5, the Elongator complex cannot properly assemble, compromising its function in both nuclear histone acetylation and cytoplasmic tRNA modification . The proper functioning of this complex is crucial for cellular processes including transcriptional elongation, translation fidelity, and cell migration.

What criteria should researchers use when selecting DERP6 antibodies?

When selecting DERP6 antibodies, researchers should first consider the specific application requirements. Available DERP6 antibodies have been validated for Western blot (working dilution range: 1:300-5000), immunohistochemistry on paraffin-embedded tissues (IHC-P, working dilution: 1:200-400), and immunofluorescence (IF, working dilution: 1:50-200) . For studies focusing on protein-protein interactions within the Elongator complex, antibodies targeting specific domains of DERP6 that mediate these interactions may be more suitable. For instance, antibodies targeting regions that interact with ELP3 or ELP4 would be valuable for co-immunoprecipitation studies . The immunogen used is also important—antibodies generated against KLH-conjugated synthetic peptides derived from human DERP6/C17orf81 (specifically from the immunogen range 221-316/316) are commercially available and have been validated across human, mouse, and rat samples .

How should researchers validate DERP6 antibody specificity?

Validating DERP6 antibody specificity requires a multi-faceted approach. First, researchers should perform Western blot analysis comparing wild-type cell lysates with those from DERP6/ELP5-depleted cells (using siRNA or CRISPR/Cas9 approaches) to confirm the absence or reduction of the specific band in depleted samples . Second, immunoprecipitation followed by mass spectrometry can verify that the antibody captures authentic DERP6 protein. Third, immunofluorescence experiments should show consistent subcellular localization patterns (primarily cytoplasmic for DERP6) and should be performed alongside specificity controls . For advanced validation, cross-reactivity testing against other Elongator complex subunits (particularly ELP1-ELP6) should be conducted to ensure the antibody does not recognize related proteins within the complex .

What are the essential controls for DERP6 antibody experiments?

Essential controls for DERP6 antibody experiments include both positive and negative controls. For positive controls, researchers should use cell types known to express DERP6 at high levels, such as liver, heart, or brain tissue samples . For negative controls, DERP6/ELP5-depleted cells are ideal, but isotype controls (using the same immunoglobulin class and host species as the DERP6 antibody) can also provide valuable information about non-specific binding . When performing immunofluorescence or immunohistochemistry, peptide competition assays using the specific immunogen peptide can confirm binding specificity . For complex assembly studies, parallel immunoprecipitations targeting other Elongator complex components (ELP1, ELP3, ELP4) should pull down DERP6/ELP5, providing internal validation of antibody functionality within the experimental system .

How can DERP6 antibodies be effectively utilized in immunofluorescence studies?

For effective immunofluorescence studies of DERP6, cell fixation methodology is critical. Paraformaldehyde (4%) fixation for 15-20 minutes at room temperature preserves most epitopes recognized by DERP6 antibodies . For permeabilization, 0.1-0.2% Triton X-100 for 5-10 minutes is typically sufficient to allow antibody access to cytoplasmic DERP6. When using FITC-conjugated DERP6 antibodies, researchers should be especially careful to protect samples from photobleaching throughout the protocol . The recommended dilution range for immunofluorescence applications is 1:50-200 . Co-staining with markers for subcellular compartments can provide valuable context—for example, DAPI for nuclear staining helps distinguish cytoplasmic DERP6 localization, while co-staining with antibodies against other Elongator complex components can reveal co-localization patterns. For studies examining the potential nuclear functions of DERP6, confocal microscopy may be necessary to clearly distinguish between cytoplasmic and nuclear fractions.

What methodological considerations are important for co-immunoprecipitation using DERP6 antibodies?

Co-immunoprecipitation (Co-IP) experiments using DERP6 antibodies require careful consideration of buffer conditions to preserve protein-protein interactions. Since DERP6/ELP5 directly connects ELP3 to ELP4 within the Elongator complex, these interactions can be captured through Co-IP . Researchers should use mild lysis buffers (e.g., 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, with protease inhibitors) to preserve protein complexes. Pre-clearing lysates with appropriate control beads reduces non-specific binding. For the immunoprecipitation step, DERP6 antibodies should be coupled to protein A/G beads according to manufacturer protocols. After overnight incubation at 4°C, beads should be washed with decreasing salt concentrations to preserve weaker interactions. Western blot analysis of the immunoprecipitates should reveal co-precipitation of other Elongator complex components, particularly ELP1, ELP3, and ELP4 . Reciprocal Co-IPs (using antibodies against other complex components) provide strong validation of the identified interactions.

How can researchers investigate DERP6's role in melanoma cell migration and invasion?

Investigating DERP6's role in melanoma cell migration and invasion requires a combination of depletion studies and functional assays. DERP6/ELP5 can be efficiently depleted using targeted siRNAs or CRISPR/Cas9-mediated knockout, with depletion confirmed via Western blotting . For migration assays, researchers should employ both wound healing (scratch) assays and Transwell migration chambers to assess two-dimensional and directional migration, respectively. For invasion assays, Matrigel-coated Transwell chambers provide a three-dimensional extracellular matrix barrier that cells must degrade to invade. Studies have demonstrated that DERP6/ELP5-depleted melanoma cells exhibit significantly decreased migration and invasive capacity, similar to the phenotypes observed with depletion of other Elongator complex components (ELP1, ELP3) . Rescue experiments using wild-type DERP6/ELP5 expression constructs, but not mutants that fail to bind ELP1 or ELP3, can restore motility in DERP6/ELP5-deficient cells, confirming specificity .

What approaches can determine DERP6's contribution to tumorigenicity?

To determine DERP6's contribution to tumorigenicity, researchers should implement both in vitro and in vivo approaches. In vitro, soft agar colony formation assays provide a measure of anchorage-independent growth, a hallmark of cancer cells. DERP6/ELP5-depleted melanoma cells demonstrate significantly reduced colony formation capacity in soft agar, suggesting impaired tumorigenic potential . For in vivo assessments, xenograft models using immunocompromised mice injected with control versus DERP6/ELP5-depleted melanoma cells can demonstrate differences in tumor establishment, growth kinetics, and metastatic potential. Additionally, researchers can investigate molecular mechanisms by examining the impact of DERP6/ELP5 depletion on established oncogenic signaling pathways through phosphorylation-specific antibodies against key signaling proteins. Correlation studies examining DERP6/ELP5 expression levels in patient-derived melanoma samples versus normal tissues or across melanoma progression stages can provide clinical relevance to these findings.

How can researchers explore DERP6's connection to p53-mediated transcriptional regulation?

Exploring DERP6's connection to p53-mediated transcriptional regulation requires integrating molecular, cellular, and genomic approaches. Researchers should first establish model systems with both wild-type p53 and p53-null backgrounds, then manipulate DERP6/ELP5 expression through overexpression or depletion approaches. Chromatin immunoprecipitation (ChIP) assays using antibodies against p53 can determine whether DERP6/ELP5 levels affect p53 binding to target gene promoters. Conversely, ChIP using DERP6 antibodies can reveal whether DERP6/ELP5 itself is recruited to p53 target genes . RNA-seq analysis comparing transcriptome changes in response to p53 activation (e.g., via DNA damage) between control and DERP6/ELP5-depleted cells can identify genes whose regulation depends on both p53 and DERP6/ELP5. Since DERP6/ELP5 functions within the Elongator complex, which affects histone acetylation, ChIP-seq for histone acetylation marks (e.g., H3K9ac, H3K14ac) can determine whether DERP6/ELP5 depletion alters the epigenetic landscape at p53 target genes.

What are common technical challenges when working with DERP6 antibodies?

Several technical challenges may arise when working with DERP6 antibodies. First, detection sensitivity may be limited by the relatively moderate expression levels of DERP6 in many cell types, requiring optimization of antibody concentration and detection methods . Second, the presence of multiple alternatively spliced isoforms can complicate band pattern interpretation in Western blots; researchers should be aware of expected molecular weights for different isoforms in their experimental system . Third, cross-reactivity with other Elongator complex components (ELP1-ELP6) may occur due to structural similarities, requiring thorough validation of antibody specificity . For immunofluorescence applications, high background may result from non-specific binding, necessitating longer blocking steps (2-3 hours) with 5% BSA or normal serum from the secondary antibody host species . Additionally, FITC-conjugated antibodies require careful handling to prevent photobleaching, including minimizing exposure to light and using anti-fade mounting media .

How should researchers interpret contradictory results between different DERP6 antibody applications?

When facing contradictory results between different DERP6 antibody applications, researchers should systematically consider several factors. First, epitope accessibility varies between applications—native protein conformation in immunoprecipitation versus denatured proteins in Western blotting versus partially preserved structures in fixed tissues for immunohistochemistry. Second, antibodies recognizing different epitopes within DERP6 may yield different results if certain domains are masked by protein-protein interactions or post-translational modifications . Third, fixation methods significantly impact epitope preservation; compare results across different fixation protocols to reconcile discrepancies. Additionally, contradictory results may reveal biologically relevant information about DERP6's diverse functions and interactions rather than technical artifacts. When possible, employ orthogonal detection methods that don't rely on antibodies, such as mass spectrometry for protein identification or RNA-seq with DERP6 knockdown for functional studies . Finally, consult the detailed antibody datasheets, which often contain specific information about validated applications and potential limitations for each antibody clone .

What analytical approaches help distinguish DERP6's multiple functional roles?

Distinguishing between DERP6's multiple functional roles—as an Elongator complex structural component, potential p53 pathway modulator, and regulator of cell migration/tumorigenicity—requires sophisticated analytical approaches. Researchers should implement domain-specific mutational analysis by generating DERP6/ELP5 constructs with mutations in regions responsible for interactions with specific partners (e.g., ELP1, ELP3, ELP4) and assess the impact on different functions . Temporal analysis using inducible expression or depletion systems can separate immediate versus delayed effects of DERP6 modulation, helping distinguish direct from indirect functions. Cell type-specific analyses comparing DERP6 functions across different cellular contexts (e.g., melanoma cells versus primary fibroblasts) can reveal tissue-specific roles. Quantitative proteomic approaches using proximity labeling methods (BioID or APEX) with DERP6 as the bait can identify context-specific interaction partners. Finally, integrating multi-omics data (proteomics, transcriptomics, and epigenomics) from DERP6-modulated systems can provide a comprehensive view of the pathways and processes affected by DERP6, allowing researchers to disentangle its diverse functional roles .

How do different DERP6 antibody formats compare in research applications?

This comparative analysis highlights the importance of selecting the appropriate antibody format based on the specific research application. For multiplexed immunofluorescence studies, FITC-conjugated antibodies eliminate potential cross-reactivity from secondary antibodies but require careful handling to prevent photobleaching . Unconjugated polyclonal antibodies offer greater flexibility in detection methods but may introduce more background . Researchers should consider these trade-offs when designing experiments targeting DERP6.

What emerging technologies might enhance DERP6 antibody-based research?

Several emerging technologies have the potential to significantly enhance DERP6 antibody-based research. Proximity labeling techniques such as BioID or APEX2 fused to DERP6 could enable comprehensive mapping of the DERP6 interactome in living cells under various conditions, providing insights into context-specific protein interactions . Super-resolution microscopy techniques (STORM, PALM, STED) combined with DERP6 antibodies could reveal fine-scale subcellular localization patterns beyond the resolution of conventional microscopy, potentially uncovering distinct pools of DERP6 with different functions. Spatial transcriptomics and in situ sequencing approaches could correlate DERP6 protein localization (detected by antibodies) with local transcriptional activity, providing insights into its role in transcriptional regulation . CRISPR-based genomic tagging of endogenous DERP6 with split fluorescent proteins or luciferase complementation systems could enable real-time visualization of protein-protein interactions involving DERP6 in living cells. Finally, computational antibody engineering approaches as described in source could enable the development of next-generation DERP6 antibodies with customized specificity profiles, allowing for selective targeting of specific DERP6 conformations or complexes.